Your browser is no longer supported. Please, upgrade your browser.
Settings
SNCA Seneca Biopharma, Inc. daily Stock Chart
SNCA [NASD]
Seneca Biopharma, Inc.
Index- P/E- EPS (ttm)-5.88 Insider Own4.76% Shs Outstand8.20M Perf Week-8.18%
Market Cap7.60M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float7.93M Perf Month-26.40%
Income-6.60M PEG- EPS next Q- Inst Own7.80% Short Float1.45% Perf Quarter22.67%
Sales0.02M P/S494.00 EPS this Y72.90% Inst Trans37.96% Short Ratio0.06 Perf Half Y-50.67%
Book/sh2.37 P/B0.39 EPS next Y- ROA-103.80% Target Price26.00 Perf Year-91.17%
Cash/sh- P/C- EPS next 5Y- ROE-145.00% 52W Range0.70 - 13.78 Perf YTD-6.32%
Dividend- P/FCF- EPS past 5Y38.10% ROI-137.70% 52W High-93.27% Beta1.57
Dividend %- Quick Ratio5.00 Sales past 5Y18.80% Gross Margin- 52W Low32.49% ATR0.18
Employees6 Current Ratio5.00 Sales Q/Q0.00% Oper. Margin- RSI (14)41.60 Volatility8.19% 11.51%
OptionableNo Debt/Eq0.00 EPS Q/Q75.40% Profit Margin- Rel Volume0.07 Prev Close0.91
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume1.83M Price0.93
Recom- SMA20-13.42% SMA50-12.88% SMA200-69.96% Volume124,989 Change1.44%
Feb-13-20 12:50PM  INVESTOR ALERT: Fields Kupka & Shukurov LLP Is Investigating Seneca Biopharma, Inc. for Potential Securities Violations and Breach of Fiduciary Duty Claims GlobeNewswire
Jan-17-20 02:00PM  Seneca Biopharma Announces Exercise of Warrants for $7.55 Million Gross Proceeds Priced At-the-Market PR Newswire +28.00%
Jan-10-20 11:00AM  Seneca Biopharma Announces Presentations at Both Sachs Associates 3rd Annual Neuroscience Innovation Forum & Biotech Showcase 2020 PR Newswire +5.74%
Seneca Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its lead product candidate is NSI-189, a chemical entity, which has been completed Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical study for the treatment-refractory depression, Angelman Syndrome, Alzheimer's disease, ischemic stroke, diabetic neuropathy, irradiation-induced cognitive deficit, and long-term potentiation enhancement. The company also develops NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease; Phase II clinical trial for the treatment of chronic ischemic stroke; and Phase I clinical trials for the treatment of chronic spinal cord injury, as well as is in preclinical study for the traumatic brain injury. In addition, it develops NSI-532, which is in preclinical study for treatment of Alzheimer's disease; and NSI-777 that is in preclinical study for treatment of human demyelinating diseases. The company was formerly known as Neuralstem, Inc. and changed its name to Seneca Biopharma, Inc. in October 2019. Seneca Biopharma, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.